Lipocine (LPCN) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lipocine (LPCN) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 53.2% versus a loss of 82.1%. Over five years, LPCN leads with a -92.3% price change compared with -100.0% for QNRX. Lipocine is the larger company by market cap ($16.4 million vs $15.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LPCN | QNRX |
|---|---|---|
| Share price | $1.48 | $3.28 |
| Market cap | $16.39M | $15.76M |
| 1-day change | -1.33% | -2.35% |
| YTD return | -81.57% | -77.27% |
| 1-year return | -53.16% | -82.07% |
| 5-year return | -92.30% | -99.99% |
| P/E ratio (TTM) | — | 7.45 |
| EPS (TTM) | $-1.32 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.98M | — |
| Revenue growth (YoY) | -82.35% | — |
| Net income (latest FY) | $-9.63M | $-15.80M |
| Operating margin | -524.69% | — |
| Net margin | -487.06% | — |
| 52-week high | $12.37 | $23.50 |
| 52-week low | $1.36 | $3.18 |
| Distance from 52-week high | -88.04% | -86.04% |
| Analyst consensus | none | none |
| Avg. price target upside | +237.84% | +565.55% |
| Average volume | 1.84M | 541.26K |
| Shares outstanding | 11.07M | 4.80M |
| Employees | 14 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed QNRX by 28.9 percentage points over the past year.
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
LPCN vs QNRX FAQ
Which is bigger, Lipocine or Quoin Pharmaceuticals?
Lipocine (LPCN) is larger, with a market capitalization of $16.39M compared with $15.76M for Quoin Pharmaceuticals (QNRX).
Which stock has performed better over the past year, LPCN or QNRX?
LPCN returned -53.16% over the past 12 months, compared with -82.07% for QNRX (price return, excluding dividends). Past performance does not predict future results.
Are Lipocine and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.